Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers

BACKGROUND: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rescigno, Pasquale, Lorente, David, Dolling, David, Ferraldeschi, Roberta, Rodrigues, Daniel Nava, Riisnaes, Ruth, Miranda, Susana, Bianchini, Diletta, Zafeiriou, Zafeiris, Sideris, Spyridon, Ferreira, Ana, Figueiredo, Ines, Sumanasuriya, Semini, Mateo, Joaquin, Perez-Lopez, Raquel, Sharp, Adam, Tunariu, Nina, de Bono, Johann S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995869/
https://www.ncbi.nlm.nih.gov/pubmed/29911685
http://dx.doi.org/10.1016/j.euo.2018.02.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995869/
https://www.ncbi.nlm.nih.gov/pubmed/29911685
http://dx.doi.org/10.1016/j.euo.2018.02.006

Ejemplares similares